Esperoct® provided effective prophylaxis with a low median ABR in all patients (aged 12 to 70 years).1,a
Are they ready for a switch to an extended half-life rFVIII? Phase 3 pivotal trial results demonstrated the efficacy of Esperoct®, with a low median annual bleed rate for adolescents, adults, and children.1
LOW MEDIAN ANNUAL BLEED RATE ACROSS AGE GROUPS
In patients aged 12 to 70 years
In patients aged 0 to <12 years
Esperoct® achieved a low median ABR in children (aged 0 to <12 years).1,b
ABR=annualized bleed rate.
aIn a phase 3, open-label study, safety, pharmacokinetics, and efficacy of Esperoct® were evaluated in PTPs aged ≥12 years with severe hemophilia A; 175 received routine prophylaxis (50 IU/kg every 4 days) and 12 adults elected to be treated on demand during the main phase. Treatment-requiring bleeds were reported by patients through diaries.2
bData shown are from a study of 68 previously treated children (34 aged 0-5 and 34 aged 6-11) who received an average dose of approximately 65 IU/kg twice weekly for 26 weeks. Median annualized bleeding rates are shown.3
TRIAL PRESCRIPTION PROGRAM
Esperoct® may be right for your hemophilia A patients who are interested in switching from their current standard or extended half-life FVIII product. Qualifying patients can now receive a trial prescription.c
To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.
cPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.